Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTOHSBA)

• DTT Name: Vascular endothelial growth factor A (VEGFA) DTT Info
• Gene Name: VEGFA

Molecule-Related Drug & Molecule List

5 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aflibercept	DMT3D5I	Central retinal vein occlusion with macular edema		Approved	[1]
Bevacizumab	DMSD1UN	Adenocarcinoma	2D40	Approved	[2]
Brolucizumab	DMW8QNG	Wet age-related macular degeneration	9B78.3Z	Approved	[3]
Faricimab	DM83SEB	Diabetic macular edema	9B71.02	Approved	[4]
Ranibizumab	DMSYPNW	Central retinal vein occlusion with macular edema		Approved	[5]

12 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Avastin+/-Tarceva	DMA86FL	Non-small-cell lung cancer	2C25.Y	Phase 3	[6]
Abicipar pegol	DM59OJ2	Diabetic macular edema	9B71.02	Phase 2	[7]
PTC299	DMP9TKE	Rheumatoid arthritis	FA20	Phase 2	[8]
RG7221	DM8J9DC	Colorectal cancer	2B91.Z	Phase 2	[9]
RO5520985	DMD3WNP	Colorectal cancer	2B91.Z	Phase 2	[10]
MP0250	DMR3VCY	Non-small-cell lung cancer	2C25.Y	Phase 1/2	[11]
SNN-0029	DMNV8SY	Lateral sclerosis	8B61	Phase 1/2	[12]
ABI-011	DM1KD7U	Lymphoma	2A80-2A86	Phase 1	[11]
AT001/r84	DMD2BIT	Solid tumour/cancer	2A00-2F9Z	Phase 1	[13]
MP-0112	DMJOMD4	Macular degeneration	9B78.3	Phase 1	[14]
Navicixizumab	DMZ2G69	Colorectal cancer	2B91.Z	Phase 1	[15]
SFLT-01	DMD2GKF	Macular degeneration	9B78.3	Phase 1	[16]

63 Patented Agent(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
1,6-naphyridine-4-ketone fused heterocyclic derivative 1	DMF6W2Y	N. A.	N. A.	Patented	[17]
3-phenyl-5-ureidoisothiazole-4-carboximide and 3-amino-5-phenylisothiazole derivative 1	DMB1JG2	Blood vessel proliferative disorder	BE2Z	Patented	[17]
Antibodie derivative 1	DMY5J23	N. A.	N. A.	Patented	[17]
Antibodie derivative 11	DMPG3Y8	N. A.	N. A.	Patented	[17]
Antibodie derivative 2	DMU7YC2	N. A.	N. A.	Patented	[17]
Antibodie derivative 3	DMNPBRG	N. A.	N. A.	Patented	[17]
Antibodie derivative 4	DM2WMGO	N. A.	N. A.	Patented	[17]
Antibodie derivative 7	DMJN37O	Solid tumour/cancer	2A00-2F9Z	Patented	[17]
Antibodie derivative 8	DM0CEJM	N. A.	N. A.	Patented	[17]
Antibodie derivative 9	DMDRJ31	Carotid artery disease	8B10	Patented	[17]
Carbamide derivative 14	DMU04PM	N. A.	N. A.	Patented	[17]
Carbamide derivative 15	DM2TDXW	N. A.	N. A.	Patented	[17]
Carbamide derivative 16	DMLPOUR	N. A.	N. A.	Patented	[17]
Carbamide derivative 17	DMUF5AC	N. A.	N. A.	Patented	[17]
Carbamide derivative 18	DMZ37XI	N. A.	N. A.	Patented	[17]
Carbamide derivative 19	DMLDXOB	N. A.	N. A.	Patented	[17]
Carbamide derivative 20	DMYSWG1	N. A.	N. A.	Patented	[17]
Carbamide derivative 21	DMD03J5	N. A.	N. A.	Patented	[17]
Carbamide derivative 22	DMC3TJI	N. A.	N. A.	Patented	[17]
Carbamide derivative 23	DM0IRPO	N. A.	N. A.	Patented	[17]
Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1	DMLZMIG	Gastric adenocarcinoma	2B72	Patented	[17]
Indoline derivative 12	DMJURBM	N. A.	N. A.	Patented	[17]
Indoline derivative 13	DM982GD	N. A.	N. A.	Patented	[17]
Indoline derivative 14	DM8DHRN	N. A.	N. A.	Patented	[17]
Indoline derivative 15	DMRFEH4	N. A.	N. A.	Patented	[17]
Indoline derivative 16	DM9AGBT	N. A.	N. A.	Patented	[17]
Indoline derivative 17	DMXSFJ8	N. A.	N. A.	Patented	[17]
Indoline derivative 18	DMX640D	N. A.	N. A.	Patented	[17]
Indoline derivative 19	DMOHITL	N. A.	N. A.	Patented	[17]
Indoline derivative 20	DM4JNLQ	N. A.	N. A.	Patented	[17]
Indoline derivative 21	DM3YPX1	N. A.	N. A.	Patented	[17]
Oxetane 3,3-dicarboxamide compound 1	DMSB09X	Virus infection	1A24-1D9Z	Patented	[17]
Oxetane 3,3-dicarboxamide compound 2	DMMCTAK	Virus infection	1A24-1D9Z	Patented	[17]
PMID28621580-Compound-WO2013036866C66	DMBTZ8I	Solid tumour/cancer	2A00-2F9Z	Patented	[17]
PMID28621580-Compound-WO2013112959C68	DM15OKA	Fibrosis	GA14-GC01	Patented	[17]
PMID28621580-Compound-WO2014079545C69	DMR58TX	N. A.	N. A.	Patented	[17]
PMID28621580-Compound-WO2015089220C70	DMX96FI	Age-related macular degeneration	9B75.0	Patented	[17]
Pyridine derivative 10	DMVL2G3	N. A.	N. A.	Patented	[17]
Pyridine derivative 11	DMF9VMW	N. A.	N. A.	Patented	[17]
Pyridine derivative 2	DMGSUIV	N. A.	N. A.	Patented	[17]
Pyridine derivative 3	DMFALQN	N. A.	N. A.	Patented	[17]
Pyridine derivative 4	DM6N8T3	Solid tumour/cancer	2A00-2F9Z	Patented	[17]
Pyridine derivative 5	DMXP6W1	N. A.	N. A.	Patented	[17]
Pyridine derivative 6	DM8NBM0	N. A.	N. A.	Patented	[17]
Pyridine derivative 7	DMYT1QN	N. A.	N. A.	Patented	[17]
Pyridine derivative 8	DMITVUY	N. A.	N. A.	Patented	[17]
Pyridine derivative 9	DMVF1BI	N. A.	N. A.	Patented	[17]
Pyrimidine derivative 10	DMBEZUY	N. A.	N. A.	Patented	[17]
Pyrimidine derivative 11	DMJ4QD5	N. A.	N. A.	Patented	[17]
Pyrimidine derivative 5	DMNET19	Blood vessel proliferative disorder	BE2Z	Patented	[17]
Pyrimidine derivative 6	DMBAHYO	Blood vessel proliferative disorder	BE2Z	Patented	[17]
Pyrimidine derivative 7	DMF6DUT	Blood vessel proliferative disorder	BE2Z	Patented	[17]
Pyrimidine derivative 8	DMVW25O	N. A.	N. A.	Patented	[17]
Pyrimidine derivative 9	DMV6U9Y	N. A.	N. A.	Patented	[17]
Quinoline and quinazoline derivative 10	DM6E1N4	N. A.	N. A.	Patented	[17]
Quinoline and quinazoline derivative 2	DM9PSI3	N. A.	N. A.	Patented	[17]
Quinoline and quinazoline derivative 3	DMGY4WO	N. A.	N. A.	Patented	[17]
Quinoline and quinazoline derivative 4	DM5VCQP	N. A.	N. A.	Patented	[17]
Quinoline and quinazoline derivative 5	DM7RQ2G	N. A.	N. A.	Patented	[17]
Quinoline and quinazoline derivative 6	DMZ2TB5	N. A.	N. A.	Patented	[17]
Quinoline and quinazoline derivative 7	DMMJEWB	N. A.	N. A.	Patented	[17]
Quinoline and quinazoline derivative 8	DMW3JH0	N. A.	N. A.	Patented	[17]
Quinoline and quinazoline derivative 9	DMBL86O	N. A.	N. A.	Patented	[17]

1 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bevasiranib	DMIEB8Y	Exudative age-related macular degeneration	9B78.3Z	Discontinued in Phase 3	[18]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] FDA Approved Drug Products from FDA Official Website. 2004. Application Number: (ANDA) 125085.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [4] Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Expert Opin Investig Drugs. 2021 Mar;30(3):193-200.
• [5] Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006 Oct;26(8):859-70.
• [6] Clinical pipeline report, company report or official report of Genentech (2009).
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study.J Neurooncol.2015 Jan;121(1):217-24.
• [9] Bispecific antibodies and their applications
• [10] Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
• [11] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [12] Clinical pipeline report, company report or official report of Neuronova.
• [13] Clinical pipeline report, company report or official report of Affitech (2011).
• [14] Treatment of exudative age-related macular degeneration with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I/II study. Am J Ophthalmol. 2014 Oct;158(4):724-732.e2.
• [15] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [16] sFLT01: a novel fusion protein with antiangiogenic activity. Mol Cancer Ther. 2011 Mar;10(3):404-15.
• [17] VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
• [18] Bevasiranib for the Treatment of Wet, Age-Related Macular Degeneration